[A24-119] Osimertinib (NSCLC, combination with pemetrexed and platinum-based chemotherapy) – Addendum to Project A24-77
Last updated 06.02.2025
Project no.:
A24-119
Commission:
Commission awarded on 10.12.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
First-line treatment of adult patients with advanced non-small cell lung cancer whose tumours have epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations
Unchanged after addendum:
hint of lesser benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A24-119_en
| Project no. | Title | Status |
|---|---|---|
| A24-77 | Osimertinib (NSCLC, combination with pemetrexed and platinum-based chemotherapy) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2025-02-06 A G-BA decision was published.